https://altoneuroscience.com/resource/bringing-imaging-biomarkers-into-clinical-reality-in-psychiatry/ 2024-10-11T10:42:44+00:00 https://altoneuroscience.com/resource/opportunities-for-use-of-neuroimaging-in-de-risking-drug-development-and-improving-clinical-outcomes-in-psychiatry-an-industry-perspective/ 2024-10-11T11:24:39+00:00 https://altoneuroscience.com/resource/machine-learning-based-identification-of-a-psychotherapy-predictive-electroencephalographic-signature-in-ptsd/ 2024-10-11T11:31:37+00:00 https://altoneuroscience.com/resource/a-data-driven-framework-for-mapping-domains-of-human-neurobiology/ 2024-10-11T11:33:47+00:00 https://altoneuroscience.com/resource/identification-of-psychiatric-disorder-subtypes-from-functional-connectivity-patterns-in-resting-state-electroencephalography/ 2024-10-11T11:35:41+00:00 https://altoneuroscience.com/resource/an-electroencephalographic-signature-predicts-antidepressant-response-in-major-depression/ 2024-10-11T11:38:39+00:00 https://altoneuroscience.com/resource/cortical-connectivity-moderators-of-antidepressant-vs-placebo-treatment-response-in-major-depressive-disorder-secondary-analysis-of-a-randomized-clinical-trial/ 2024-10-11T11:42:01+00:00 https://altoneuroscience.com/resource/an-electroencephalography-connectomic-profile-of-posttraumatic-stress-disorder/ 2024-10-11T11:44:01+00:00 https://altoneuroscience.com/resource/individual-patterns-of-abnormality-in-resting-state-functional-connectivity-reveal-two-data-driven-ptsd-subgroups/ 2024-10-11T11:46:27+00:00 https://altoneuroscience.com/resource/global-connectivity-and-local-excitability-changes-underlie-antidepressant-effects-of-repetitive-transcranial-magnetic-stimulation/ 2024-10-11T11:52:10+00:00 https://altoneuroscience.com/resource/using-fmri-connectivity-to-define-a-treatment-resistant-form-of-post-traumatic-stress-disorder/ 2024-10-14T10:08:40+00:00 https://altoneuroscience.com/resource/brain-regulation-of-emotional-conflict-predicts-antidepressant-treatment-response-for-depression/ 2024-10-14T10:10:36+00:00 https://altoneuroscience.com/resource/artist-a-fully-automated-artifact-rejection-algorithm-for-single-pulse-tms-eeg-data/ 2024-10-14T10:12:48+00:00 https://altoneuroscience.com/resource/ptsd-psychotherapy-outcome-predicted-by-brain-activation-during-emotional-reactivity-and-regulation/ 2024-10-14T10:14:27+00:00 https://altoneuroscience.com/resource/identification-and-prospective-replication-of-a-cognitive-biomarker-for-predicting-the-antidepressant-effect-of-alto-100-a-novel-pro-plasticity-drug-in-patients-with-major-depression-results-from-a/ 2024-10-14T10:19:54+00:00 https://altoneuroscience.com/resource/identification-of-brain-behavior-based-pro-cognitive-pharmacodynamic-effects-for-alto-101-in-healthy-volunteers-results-from-a-randomized-double-blind-phase-1-study-and-a-pk-tolerability-phase-1-stu/ 2024-10-14T10:23:42+00:00 https://altoneuroscience.com/resource/baseline-cognition-is-not-associated-with-depression-outcomes-with-vortioxetine-for-major-depressive-disorder-findings-from-placebo-controlled-trials/ 2024-10-14T10:35:57+00:00 https://altoneuroscience.com/resource/identification-and-prospective-replication-of-an-eeg-biomarker-for-predicting-the-antidepressant-effect-of-alto-300-in-patients-with-major-depression-results-from-large-phase-2a-studies/ 2024-10-14T10:38:17+00:00 https://altoneuroscience.com/resource/a-biomarker-based-enrichment-strategy-for-neuropsychiatric-drug-development-examples-from-two-ongoing-phase-2b-studies/ 2024-10-14T10:44:51+00:00 https://altoneuroscience.com/resource/identification-and-prospective-replication-of-electrophysiological-markers-linked-to-cognitive-impairment-in-schizophrenia-cias/ 2024-10-14T10:46:38+00:00 https://altoneuroscience.com/resource/verbal-memory-and-inhibitory-control-predict-functional-capacity-and-impairment-in-major-depressive-disorder-a-secondary-analysis-of-the-remind-switch-trial/ 2024-10-14T10:48:24+00:00 https://altoneuroscience.com/resource/prevalence-and-correlates-of-cognitive-impairment-in-depression-findings-from-the-texas-resilience-against-depression-study/ 2024-10-14T10:50:32+00:00 https://altoneuroscience.com/resource/dysregulation-of-adult-hippocampal-neuroplasticity-in-major-depression-pathogenesis-and-therapeutic-implications/ 2024-10-14T10:51:52+00:00 https://altoneuroscience.com/resource/unveiling-the-associations-between-eeg-indices-and-cognitive-deficits-in-schizophrenia-spectrum-disorders-a-systematic-review/ 2024-10-14T10:53:38+00:00 https://altoneuroscience.com/resource/progress-and-pitfalls-in-developing-agents-to-treat-neurocognitive-deficits-associated-with-schizophrenia/ 2024-10-14T10:55:06+00:00 https://altoneuroscience.com/resource/anhedonia-as-a-central-factor-in-depression-neural-mechanisms-revealed-from-preclinical-to-clinical-evidence/ 2024-10-14T10:56:34+00:00 https://altoneuroscience.com/resource/phosphodiesterase-4-enzyme-as-a-therapeutic-target-in-neurological-disorders/ 2024-10-14T10:58:09+00:00 https://altoneuroscience.com/resource/the-effects-of-roflumilast-a-phosphodiesterase-type-4-inhibitor-on-eeg-biomarkers-in-schizophrenia-a-randomised-controlled-trial/ 2024-10-14T11:00:39+00:00 https://altoneuroscience.com/resource/a-phase-2-double-blind-placebo-controlled-study-of-nsi-189-phosphate-a-neurogenic-compound-among-outpatients-with-major-depressive-disorder/ 2024-10-14T11:02:36+00:00 https://altoneuroscience.com/resource/central-nervous-system-effects-of-the-histamine‐3-receptor-antagonist-cep‐26401-in-comparison-with-modafinil-and-donepezil-after-a-single-dose-in-a-cross‐over-study-in-health/ 2024-10-14T11:03:59+00:00 https://altoneuroscience.com/resource/the-molecular-and-cellular-mechanisms-of-depression-a-focus-on-reward-circuitry/ 2024-10-14T11:05:20+00:00 https://altoneuroscience.com/resource/histamine-h3-receptor-antagonists-inverse-agonists-where-do-they-go/ 2024-10-14T11:07:29+00:00 https://altoneuroscience.com/resource/comparative-efficacy-and-acceptability-of-21-antidepressant-drugs-for-the-acute-treatment-of-adults-with-major-depressive-disorder-a-systematic-review-and-network-meta-analysis/ 2024-10-14T11:08:53+00:00 https://altoneuroscience.com/resource/adult-hippocampal-neurogenesis-and-cognitive-flexibility-linking-memory-and-mood/ 2024-10-14T11:10:38+00:00 https://altoneuroscience.com/resource/the-neurogenic-compound-nsi-189-phosphate-a-novel-multi-domain-treatment-capable-of-pro-cognitive-and-antidepressant-effects/ 2024-10-14T11:12:06+00:00 https://altoneuroscience.com/resource/a-phase-1b-randomized-double-blind-placebo-controlled-multiple-dose-escalation-study-of-nsi-189-phosphate-a-neurogenic-compound-in-depressed-patients/ 2024-10-14T11:13:33+00:00 https://altoneuroscience.com/resource/sustained-efficacy-of-agomelatine-10-mg-25-mg-and-25-50-mg-on-depressive-symptoms-and-functional-outcomes-in-patients-with-major-depressive-disorder-a-placebo-controlled-study-over-6-months/ 2024-10-14T11:14:52+00:00 https://altoneuroscience.com/resource/subgroup-analysis-of-the-non-interventional-study-vivaldi-agomelatine-in-treatment-naive-patients-in-combination-therapy-and-after-treatment-switch/ 2024-10-14T11:15:58+00:00 https://altoneuroscience.com/resource/the-mechanism-efficacy-and-tolerability-profile-of-agomelatine/ 2024-10-14T11:17:02+00:00 https://altoneuroscience.com/resource/the-role-of-phosphodiesterases-in-schizophrenia/ 2024-10-14T11:18:26+00:00 https://altoneuroscience.com/resource/agomelatine-the-first-melatonergic-antidepressant-discovery-characterization-and-development/ 2024-10-14T11:19:35+00:00 https://altoneuroscience.com/resource/brain-histamine-and-schizophrenia-potential-therapeutic-applications-of-h3-receptor-inverse-agonists-studied-with-bf2-649/ 2024-10-14T11:20:51+00:00 https://altoneuroscience.com/resource/selective-effects-of-psychotherapy-on-frontopolar-cortical-function-in-ptsd/ 2024-10-14T11:27:50+00:00 https://altoneuroscience.com/resource/effects-of-alto-203-on-positive-emotion-and-reward-processing-methods-and-supporting-data-for-an-ongoing-phase-2-proof-of-concept-study/ 2024-10-15T08:24:19+00:00 https://altoneuroscience.com/resource/validation-of-assessments-for-reward-processing-for-use-in-a-phase-2-study-of-a-novel-histamine-h3-inverse-agonist-alto-203-in-major-depression/ 2024-12-11T08:08:33+00:00 https://altoneuroscience.com/resource/neural-and-molecular-mechanistic-correlates-of-an-eeg-biomarker-predictive-of-the-antidepressant-response-to-alto-300-in-patients-with-major-depression/ 2024-12-11T08:08:39+00:00 https://altoneuroscience.com/resource/prevalence-and-correlates-of-cognitive-impairment-in-depression-findings-from-the-texas-resilience-against-depression-study-2/ 2024-12-11T08:08:46+00:00 https://altoneuroscience.com/resource/standardization-of-eeg-enrichment-marker-acquisitions-in-a-randomized-double-blind-placebo-controlled-study-of-alto-300-in-adults-with-major-depressive-disorders/ 2025-02-19T09:56:19+00:00 https://altoneuroscience.com/resource/alto-101-modulates-eeg-biomarkers-linked-to-cognitive-impairment-in-schizophrenia-evidence-from-a-phase-1-trial-and-bsnip-studies/ 2025-04-03T09:07:01+00:00 https://altoneuroscience.com/resource/prospective-replication-and-application-of-an-eeg-based-placebo-response-prediction-biomarker-in-randomized-controlled-trials-in-depression/ 2025-04-25T08:25:51+00:00 https://altoneuroscience.com/resource/gamma-band-eeg-sample-entropy-a-patient-selection-biomarker-for-alto-300-is-increased-by-dopamine-depletion-in-humans-and-mice-2/ 2025-04-25T08:25:55+00:00 https://altoneuroscience.com/resource/translational-utility-of-erp-and-time-frequency-features-for-cognitive-impairment-in-schizophrenia-preclinical-evaluation-of-mk-801-deficits-and-rescue-by-alto-101/ 2025-04-25T08:26:00+00:00 https://altoneuroscience.com/resource/an-eeg-biomarker-for-predicting-placebo-response-in-major-depressive-disorder-development-and-validation-across-open-label-and-double-blind-trials/ 2025-04-25T08:26:04+00:00 https://altoneuroscience.com/resource/alto-203-a-novel-histamine-h3-inverse-agonist-increase-sucrose-preference-in-dopamine-depleted-rats/ 2025-04-25T08:26:08+00:00 https://altoneuroscience.com/resource/gamma-band-eeg-sample-entropy-a-patient-selection-biomarker-for-alto-300-is-increased-by-dopamine-depletion-in-humans-and-mice/ 2025-04-29T19:04:41+00:00 https://altoneuroscience.com/resource/1805/ 2025-05-28T09:27:02+00:00 https://altoneuroscience.com/resource/pramipexole-augmentation-for-the-acute-phase-of-treatment-resistant-unipolar-depression-a-placebo-controlled-double-blind-randomised-trial-in-the-uk/ 2025-06-27T16:38:23+00:00